Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextro Combo is a multi-ingredient pharmaceutical product typically formulated for the symptomatic relief of the common cold, allergic rhinitis, and non-productive cough. It most commonly refers to a fixed-dose combination of dextromethorphan hydrobromide (an antitussive), phenylephrine hydrochloride (a nasal decongestant), and chlorpheniramine maleate (an antihistamine). Dextromethorphan acts centrally on the cough center in the medulla to elevate the cough threshold. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that induces vasoconstriction in the respiratory tract mucosa, thereby reducing swelling and congestion. Chlorpheniramine is a first-generation H1-receptor antagonist that alleviates allergic symptoms such as sneezing, itching, and rhinorrhea. While primarily available as an over-the-counter (OTC) medication in various international markets, the name is also occasionally used in veterinary medicine for dextrose-based electrolyte solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dextro Combo.